Error in the current PBS listings for brentuximab vedotin for Stage III or IV CD30 positive Hodgkin lymphoma, listed on 1 November 2025

Page last updated: 11 November 2025

The current clinical criteria for brentuximab vedotin for the treatment of Stage III or IV CD30 positive Hodgkin lymphoma (PBS item codes 15080Q, 15098P) will be updated to allow use of dexamethasone when required for antiemetic purposes.

The clinical criteria for these item codes should be: “The treatment must not be in combination with (i) etoposide (ii) cyclophosphamide”. The current PBS listings include (iii) dexamethasone, which will be deleted with the update.          

This error will not cause a disruption in the treatment protocol for existing patients or delay the commencement of treatment for new patients. Prescribers can continue to seek authority approval from Services Australia following their usual workflow processes.  

The clinical criteria for item codes 15080Q and 15098P will be corrected in the PBS schedule from 1 January 2026. 

An Erratum is available on the Publications page.